|
Name |
(1R,5R)-1,8-Dimethyl-4-(propan-2-ylidene)spiro[4.5]dec-7-ene
|
| Molecular Formula | C15H24 | |
| IUPAC Name* |
(1R,5R)-1,8-dimethyl-4-propan-2-ylidenespiro[4.5]dec-8-ene
|
|
| SMILES |
C[C@@H]1CCC(=C(C)C)[C@@]12CCC(=CC2)C
|
|
| InChI |
InChI=1S/C15H24/c1-11(2)14-6-5-13(4)15(14)9-7-12(3)8-10-15/h7,13H,5-6,8-10H2,1-4H3/t13-,15+/m1/s1
|
|
| InChIKey |
HMKLOOMRRZKSNM-HIFRSBDPSA-N
|
|
| Synonyms |
.beta.-alaskene; delta-Acoradiene; (.+/-.)-.beta.-Alaskene; (1R,5R)-1,8-Dimethyl-4-(propan-2-ylidene)spiro[4.5]dec-7-ene; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, cis-; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, (1R,5R)-rel-; Spiro[4.5]dec-7-ene, 1,8-dimethyl-4-(1-methylethylidene)-, cis-(.+/-.)-; 28400-13-7
|
|
| CAS | NA | |
| PubChem CID | 6428281 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 204.35 | ALogp: | 4.6 |
| HBD: | 0 | HBA: | 0 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
| Heavy Atoms: | 15 | QED Weighted: | 0.472 |
| Caco-2 Permeability: | -4.449 | MDCK Permeability: | 0.00001490 |
| Pgp-inhibitor: | 0.12 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.97 |
| 30% Bioavailability (F30%): | 0.579 |
| Blood-Brain-Barrier Penetration (BBB): | 0.102 | Plasma Protein Binding (PPB): | 95.84% |
| Volume Distribution (VD): | 5.522 | Fu: | 3.14% |
| CYP1A2-inhibitor: | 0.753 | CYP1A2-substrate: | 0.474 |
| CYP2C19-inhibitor: | 0.58 | CYP2C19-substrate: | 0.903 |
| CYP2C9-inhibitor: | 0.509 | CYP2C9-substrate: | 0.84 |
| CYP2D6-inhibitor: | 0.062 | CYP2D6-substrate: | 0.317 |
| CYP3A4-inhibitor: | 0.172 | CYP3A4-substrate: | 0.215 |
| Clearance (CL): | 10.267 | Half-life (T1/2): | 0.173 |
| hERG Blockers: | 0.019 | Human Hepatotoxicity (H-HT): | 0.249 |
| Drug-inuced Liver Injury (DILI): | 0.045 | AMES Toxicity: | 0.007 |
| Rat Oral Acute Toxicity: | 0.019 | Maximum Recommended Daily Dose: | 0.047 |
| Skin Sensitization: | 0.905 | Carcinogencity: | 0.268 |
| Eye Corrosion: | 0.819 | Eye Irritation: | 0.975 |
| Respiratory Toxicity: | 0.088 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000786 | ![]() |
0.464 | D04SFH | ![]() |
0.225 | ||
| ENC002392 | ![]() |
0.464 | D0I2SD | ![]() |
0.225 | ||
| ENC002990 | ![]() |
0.390 | D04GJN | ![]() |
0.225 | ||
| ENC000395 | ![]() |
0.388 | D0V2JK | ![]() |
0.223 | ||
| ENC001077 | ![]() |
0.377 | D07BSQ | ![]() |
0.221 | ||
| ENC001135 | ![]() |
0.367 | D02CNR | ![]() |
0.216 | ||
| ENC000588 | ![]() |
0.367 | D0W6DG | ![]() |
0.207 | ||
| ENC001637 | ![]() |
0.346 | D0F1UL | ![]() |
0.207 | ||
| ENC000388 | ![]() |
0.346 | D0Z1XD | ![]() |
0.200 | ||
| ENC003255 | ![]() |
0.344 | D0F2AK | ![]() |
0.200 | ||